AbbVie reports decrease in Humira® revenues due to biosimilar competition

Nov 1, 2019

AbbVie releases Third-Quarter results, showing an overall decrease in Humira® revenues of 3.7% due to biosimilar competition. While Humira® revenues continued to increase in the US by 9.6%, internationally revenues decreased by 33.5%.

Print Page Mail Article